Merck (NYSE:MRK) has ended acquisition talks with Revolution Medicines after the parties could not agree on valuation. The company is investing $30 million in Eikon Therapeutics ahead of Eikon's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results